Current Report Filing (8-k)
January 21 2021 - 1:05PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): January 12, 2021
GLOBAL
WHOLEHEALTH PARTNERS CORPORATION
(Exact
name of registrant as specified in its charter)
Nevada
|
000-56035
|
46-2316220
|
(State
or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification No.)
|
2227
Avenida Oliva
San
Clemente, CA
|
92673
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code (714) 392-9752
N/A
(Former name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
¨
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Section
1 - Registrant’s Business and Operations
Item
1.01 Entry into a Material Definitive Agreement.
On
January 12, 2021, Global Wholehealth Partners Corporation (the “Company”) entered into a License
Agreement (“Agreement”) with Charles Strongo. Under the terms of the Agreement, the Company has the exclusive
license to manufacture, sell and license to be manufactured the only Biodegradable plastic for medical devices. The devices
are cassette test plastic midstream, urine cups, and any medical device made from plastic. Provisional Patent
number 63/054,139.
The Company agreed to issue 3,000,000 shares of common stock and
pay a 2% fee of gross sales from use of the patent. The duration of the agreement is for an initial period of five years
commencing on January 12, 2021.
The
foregoing description of the Agreement does not purport to be completed and is qualified in its entirety by reference to the Agreement,
which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Section
9 – Financial Statement and Exhibits
Item 9.01 Financial Statements and Exhibits.
Exhibit
No.
|
Document
|
Location
|
10.1
|
Licensing agreement dated January 12, 2021
|
Filed Herewith
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
GLOBAL
WHOLEHEALTH PARTNERS CORPORATION
(Registrant)
|
Date:
January 21, 2021
|
By:
/s/ Charles Strongo
Charles Strongo
Chief Executive Officer
|
Global Wholehealth Partn... (CE) (USOTC:GWHP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Global Wholehealth Partn... (CE) (USOTC:GWHP)
Historical Stock Chart
From Sep 2023 to Sep 2024